WASHINGTON TRUST Co grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 16.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,892 shares of the company's stock after buying an additional 2,671 shares during the period. WASHINGTON TRUST Co's holdings in Eli Lilly and Company were worth $11,013,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company during the 3rd quarter worth $27,000. Retirement Group LLC increased its position in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company's stock worth $27,000 after purchasing an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new position in shares of Eli Lilly and Company in the second quarter worth $33,000. Legacy Financial Group LLC bought a new position in shares of Eli Lilly and Company in the third quarter worth $35,000. Finally, Optiver Holding B.V. bought a new position in shares of Eli Lilly and Company in the third quarter worth $36,000. Institutional investors own 82.53% of the company's stock.
Wall Street Analysts Forecast Growth
LLY has been the topic of a number of recent analyst reports. Bank of America raised their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an "overweight" rating in a research report on Friday, March 15th. TheStreet upgraded Eli Lilly and Company from a "c+" rating to a "b" rating in a research report on Friday, March 8th. Barclays lifted their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an "overweight" rating in a research report on Wednesday, February 7th. Finally, Wells Fargo & Company lifted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an "overweight" rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $689.52.
Check Out Our Latest Research Report on LLY
Eli Lilly and Company Trading Up 0.5 %
Shares of Eli Lilly and Company stock traded up $3.79 during midday trading on Wednesday, reaching $778.69. The company had a trading volume of 2,297,294 shares, compared to its average volume of 3,236,753. The stock has a fifty day moving average price of $727.96 and a 200 day moving average price of $636.01. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a market cap of $739.88 billion, a PE ratio of 133.96, a P/E/G ratio of 1.70 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm's quarterly revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.09 earnings per share. On average, equities analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current year.
Insiders Place Their Bets
In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 14,388 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total value of $9,068,468.64. Following the completion of the sale, the insider now directly owns 99,754,422 shares in the company, valued at $62,873,217,098.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is owned by corporate insiders.
About Eli Lilly and Company
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Further Reading
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
